FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025232743> ?p ?o ?g. }

• W2025232743 endingPage "451" @default.
• W2025232743 startingPage "443" @default.
• W2025232743 abstract "Background Many patients with asthma have an IgE-mediated allergic component to the disease. Omalizumab, a monoclonal anti-IgE antibody, has demonstrated clinical efficacy in patients with allergic asthma. The effects of omalizumab on inflammation in asthma are not completely understood. Objectives To evaluate the effects of omalizumab on allergen- and growth factor-stimulated proinflammatory cytokine and nitric oxide (NO) production in human bronchial epithelial cells (BECs) and to compare them to the effects of budesonide, a corticosteroid with known anti-inflammatory properties. Methods Human BECs were stimulated in duplicate with interleukin 1β (IL-1β), 100 U/mL; ragweed, 10 μg/mL; dust mite, 1,000 AU; and epithelial growth factor, 40 ng/mL; and either 10−7 M budesonide or 0.1 μg/mL of omalizumab in a 4% dust mite atopic serum medium for 6 and 24 hours in 5% carbon dioxide at 37°C. Tumor necrosis factor α and transforming growth factor β expression and production and IL-4, IL-13, and NO production were assayed using gene-specific messenger RNA or sensitive enzyme-linked immunosorbent assays. Results Omalizumab inhibited the expression and of production proinflammatory cytokines and growth factor in antigen-stimulated BECs at 6 and 24 hours. Production of NO was inhibited at 6 hours and increased at 24 hours by omalizumab and budesonide. Conclusions The effects of omalizumab were similar to those of budesonide. These results, consistent with previously reported evidence of anti-inflammatory effects of omalizumab, demonstrate that omalizumab may reduce airway inflammation and probably contributes to decreased airway remodeling in patients with asthma. Many patients with asthma have an IgE-mediated allergic component to the disease. Omalizumab, a monoclonal anti-IgE antibody, has demonstrated clinical efficacy in patients with allergic asthma. The effects of omalizumab on inflammation in asthma are not completely understood. To evaluate the effects of omalizumab on allergen- and growth factor-stimulated proinflammatory cytokine and nitric oxide (NO) production in human bronchial epithelial cells (BECs) and to compare them to the effects of budesonide, a corticosteroid with known anti-inflammatory properties. Human BECs were stimulated in duplicate with interleukin 1β (IL-1β), 100 U/mL; ragweed, 10 μg/mL; dust mite, 1,000 AU; and epithelial growth factor, 40 ng/mL; and either 10−7 M budesonide or 0.1 μg/mL of omalizumab in a 4% dust mite atopic serum medium for 6 and 24 hours in 5% carbon dioxide at 37°C. Tumor necrosis factor α and transforming growth factor β expression and production and IL-4, IL-13, and NO production were assayed using gene-specific messenger RNA or sensitive enzyme-linked immunosorbent assays. Omalizumab inhibited the expression and of production proinflammatory cytokines and growth factor in antigen-stimulated BECs at 6 and 24 hours. Production of NO was inhibited at 6 hours and increased at 24 hours by omalizumab and budesonide. The effects of omalizumab were similar to those of budesonide. These results, consistent with previously reported evidence of anti-inflammatory effects of omalizumab, demonstrate that omalizumab may reduce airway inflammation and probably contributes to decreased airway remodeling in patients with asthma." @default.
• W2025232743 created "2016-06-24" @default.
• W2025232743 creator A5002300648 @default.
• W2025232743 creator A5033862057 @default.
• W2025232743 creator A5034174597 @default.
• W2025232743 date "2005-11-01" @default.
• W2025232743 modified "2023-09-27" @default.
• W2025232743 title "Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells" @default.
• W2025232743 cites W1910182345 @default.
• W2025232743 cites W1967215794 @default.
• W2025232743 cites W1971325026 @default.
• W2025232743 cites W1973104644 @default.
• W2025232743 cites W1973155194 @default.
• W2025232743 cites W1973743859 @default.
• W2025232743 cites W1978006696 @default.
• W2025232743 cites W1982140654 @default.
• W2025232743 cites W2009572106 @default.
• W2025232743 cites W2009608314 @default.
• W2025232743 cites W2014592293 @default.
• W2025232743 cites W2017754261 @default.
• W2025232743 cites W2019860835 @default.
• W2025232743 cites W2036759594 @default.
• W2025232743 cites W2065071227 @default.
• W2025232743 cites W2069819735 @default.
• W2025232743 cites W2079927465 @default.
• W2025232743 cites W2098968578 @default.
• W2025232743 cites W2103255487 @default.
• W2025232743 cites W2103675711 @default.
• W2025232743 cites W2107792698 @default.
• W2025232743 cites W2110052844 @default.
• W2025232743 cites W2114436422 @default.
• W2025232743 cites W2131708667 @default.
• W2025232743 cites W2149147476 @default.
• W2025232743 cites W2151539516 @default.
• W2025232743 cites W2152381821 @default.
• W2025232743 cites W2160953471 @default.
• W2025232743 cites W2169949930 @default.
• W2025232743 cites W2171998819 @default.
• W2025232743 cites W4313333802 @default.
• W2025232743 cites W46120663 @default.
• W2025232743 doi "https://doi.org/10.1016/s1081-1206(10)61170-2" @default.
• W2025232743 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16312167" @default.
• W2025232743 hasPublicationYear "2005" @default.
• W2025232743 type Work @default.
• W2025232743 sameAs 2025232743 @default.
• W2025232743 citedByCount "38" @default.
• W2025232743 countsByYear W20252327432012 @default.
• W2025232743 countsByYear W20252327432013 @default.
• W2025232743 countsByYear W20252327432014 @default.
• W2025232743 countsByYear W20252327432015 @default.
• W2025232743 countsByYear W20252327432016 @default.
• W2025232743 countsByYear W20252327432017 @default.
• W2025232743 countsByYear W20252327432018 @default.
• W2025232743 countsByYear W20252327432019 @default.
• W2025232743 countsByYear W20252327432020 @default.
• W2025232743 countsByYear W20252327432021 @default.
• W2025232743 countsByYear W20252327432023 @default.
• W2025232743 crossrefType "journal-article" @default.
• W2025232743 hasAuthorship W2025232743A5002300648 @default.
• W2025232743 hasAuthorship W2025232743A5033862057 @default.
• W2025232743 hasAuthorship W2025232743A5034174597 @default.
• W2025232743 hasConcept C141105273 @default.
• W2025232743 hasConcept C159654299 @default.
• W2025232743 hasConcept C164027704 @default.
• W2025232743 hasConcept C17991360 @default.
• W2025232743 hasConcept C203014093 @default.
• W2025232743 hasConcept C2776042228 @default.
• W2025232743 hasConcept C2776136866 @default.
• W2025232743 hasConcept C2776914184 @default.
• W2025232743 hasConcept C2778166374 @default.
• W2025232743 hasConcept C2778564945 @default.
• W2025232743 hasConcept C2778690821 @default.
• W2025232743 hasConcept C71924100 @default.
• W2025232743 hasConceptScore W2025232743C141105273 @default.
• W2025232743 hasConceptScore W2025232743C159654299 @default.
• W2025232743 hasConceptScore W2025232743C164027704 @default.
• W2025232743 hasConceptScore W2025232743C17991360 @default.
• W2025232743 hasConceptScore W2025232743C203014093 @default.
• W2025232743 hasConceptScore W2025232743C2776042228 @default.
• W2025232743 hasConceptScore W2025232743C2776136866 @default.
• W2025232743 hasConceptScore W2025232743C2776914184 @default.
• W2025232743 hasConceptScore W2025232743C2778166374 @default.
• W2025232743 hasConceptScore W2025232743C2778564945 @default.
• W2025232743 hasConceptScore W2025232743C2778690821 @default.
• W2025232743 hasConceptScore W2025232743C71924100 @default.
• W2025232743 hasIssue "5" @default.
• W2025232743 hasLocation W20252327431 @default.
• W2025232743 hasLocation W20252327432 @default.
• W2025232743 hasOpenAccess W2025232743 @default.
• W2025232743 hasPrimaryLocation W20252327431 @default.
• W2025232743 hasRelatedWork W12465354 @default.
• W2025232743 hasRelatedWork W1978006696 @default.
• W2025232743 hasRelatedWork W2015379751 @default.
• W2025232743 hasRelatedWork W2023726491 @default.
• W2025232743 hasRelatedWork W2101202640 @default.
• W2025232743 hasRelatedWork W2128002469 @default.
• W2025232743 hasRelatedWork W2160953471 @default.
• W2025232743 hasRelatedWork W2354077771 @default.

• next